Scholarlink

Background <p>Indoor residual spraying (IRS) remains a core malaria vector control intervention, but widespread insecticide resistance threatens its effectiveness. VECTRON™ T500, containing broflanilide, represents a novel IRS product with a new mode of action targeting GABA receptors.</p> Methods <p>A two-arm non-inferiority study was conducted in Bar Olengo, Siaya County, Kenya, between June and November 2024. Twenty-five structures per arm were sprayed with either VECTRON™ T500 (100&#xa0;mg a.i/m<sup>2</sup>) or Actellic™ 300CS (1&#xa0;g a.i/m<sup>2</sup>), with five water-sprayed controls. Residual efficacy was assessed using world health organization (WHO) cone bioassays with pyrethroid-resistant <i>Anopheles gambiae </i>sensu stricto (<i>s.s</i>.) Bungoma strain and susceptible Kisumu strain monthly for six months. Wild vector susceptibility to insecticides, community acceptability, and adverse events were evaluated.</p> Results <p>VECTRON™ T500 maintained significantly higher mortality than Actellic™ 300CS throughout six months on both wall types. Against resistant <i>An. gambiae s.s.</i> Bungoma strain, VECTRON™ T500 achieved 98.73 ± 3.51% mortality (95% CI 97.95–99.51%) compared to 80.22 ± 11.23% for Actellic™ 300CS (95% CI 77.72–82.72%; t₇₈ = −&#xa0;10.15, p &lt; 0.001, Cohen's d = 2.27). For susceptible Kisumu strain, VECTRON™ T500 maintained 100% mortality versus 89.60 ± 6.34% for Actellic™ 300CS (95% CI 88.19–91.01%; t₇₈ = 10.53, p &lt; 0.001, Cohen's d = 2.38). Actellic™ 300CS efficacy declined below 80% after month 4, while VECTRON™ T500 remained &gt; 95% effective throughout. Wild <i>An. gambiae </i>sensu lato (<i>s.l</i>.) and <i>Anopheles funestus s.l.</i> showed 100% susceptibility to broflanilide with no cross-resistance detected. No adverse events occurred in VECTRON™ T500 households versus 8% (12/150) in Actellic™ 300CS households. Community acceptance was 100% for VECTRON™ T500 versus 99.33% (149/150) for Actellic™ 300CS, though this difference was not statistically significant.</p> Conclusions <p>VECTRON™ T500 demonstrated superior residual efficacy, excellent safety profile, and high community acceptance compared to Actellic™ 300CS. Its novel mode of action and absence of cross-resistance to pirimiphos-methyl and pyrethroids make it valuable for insecticide resistance management in malaria vector control programmes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Community evaluation of VECTRON™ T500 (broflanilide) for indoor residual spraying for malaria vector control in Siaya county, Kenya

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月29日

查看全文
  • Celestine N. Wekesa,
  • Brian Polo,
  • Margaret Muchoki,
  • Seline Omondi,
  • Mathew Kipsum,
  • Bernard Abong’o,
  • Maxwell G. Machani,
  • Teresa Bange,
  • Ismael Abbey,
  • Paul Kiptoo,
  • Patrick Mburugu,
  • Kibor Keitany,
  • David Sang,
  • Edith Ramaita,
  • Eric Ochomo

摘要

Background

Indoor residual spraying (IRS) remains a core malaria vector control intervention, but widespread insecticide resistance threatens its effectiveness. VECTRON™ T500, containing broflanilide, represents a novel IRS product with a new mode of action targeting GABA receptors.

Methods

A two-arm non-inferiority study was conducted in Bar Olengo, Siaya County, Kenya, between June and November 2024. Twenty-five structures per arm were sprayed with either VECTRON™ T500 (100 mg a.i/m2) or Actellic™ 300CS (1 g a.i/m2), with five water-sprayed controls. Residual efficacy was assessed using world health organization (WHO) cone bioassays with pyrethroid-resistant Anopheles gambiae sensu stricto (s.s.) Bungoma strain and susceptible Kisumu strain monthly for six months. Wild vector susceptibility to insecticides, community acceptability, and adverse events were evaluated.

Results

VECTRON™ T500 maintained significantly higher mortality than Actellic™ 300CS throughout six months on both wall types. Against resistant An. gambiae s.s. Bungoma strain, VECTRON™ T500 achieved 98.73 ± 3.51% mortality (95% CI 97.95–99.51%) compared to 80.22 ± 11.23% for Actellic™ 300CS (95% CI 77.72–82.72%; t₇₈ = − 10.15, p < 0.001, Cohen's d = 2.27). For susceptible Kisumu strain, VECTRON™ T500 maintained 100% mortality versus 89.60 ± 6.34% for Actellic™ 300CS (95% CI 88.19–91.01%; t₇₈ = 10.53, p < 0.001, Cohen's d = 2.38). Actellic™ 300CS efficacy declined below 80% after month 4, while VECTRON™ T500 remained > 95% effective throughout. Wild An. gambiae sensu lato (s.l.) and Anopheles funestus s.l. showed 100% susceptibility to broflanilide with no cross-resistance detected. No adverse events occurred in VECTRON™ T500 households versus 8% (12/150) in Actellic™ 300CS households. Community acceptance was 100% for VECTRON™ T500 versus 99.33% (149/150) for Actellic™ 300CS, though this difference was not statistically significant.

Conclusions

VECTRON™ T500 demonstrated superior residual efficacy, excellent safety profile, and high community acceptance compared to Actellic™ 300CS. Its novel mode of action and absence of cross-resistance to pirimiphos-methyl and pyrethroids make it valuable for insecticide resistance management in malaria vector control programmes.